Enabling durable treatment options in oncology

We are building a pipeline of uniquely assembled, highly stable ADCs by leveraging proprietary conjugation, linker and payload technologies that enable us to utilize previously inaccessible targeting molecules and novel payloads. We are currently advancing two proprietary lead candidates with first-in-class potential in solid tumors targeting the most deadliest cancers globally. Our goal is to consolidate the knowledge gained over the last 20 years and translating it into meaningful therapeutic benefits to broaden the treatment horizon of ADCs.

Proprietary programs

Program

Discovery

Preclinical

Phase I

TUB-030targeting 5T4

Discovery

Preclinical

Phase I

multiple solid cancers

More Info

TUB-030

TUB-030 is directed against the cancer antigen 5T4, expressed in a wide range of solid tumor indications. It is using Tubulis´proprietary P5 conjugation chemistry and shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index

TUB-040targeting Napi2b

Discovery

Preclinical

Phase I

ovarian, NSCLC

More Info

TUB-040

TUB-040 is a novel Napi2b-targeting ADC based on Tubulis´ proprietary P5 conjugation technology und its Tubutecan payload platform. Napi2b is a well-characterized target in ovarian and lung cancer. TUB-040 is optimized for long-lasting, durable tumor engagement and minimal off-target toxicity.

TUB-050target undisclosed

Discovery

Preclinical

Phase I

solid cancers

TUB-050

Detailed Content Here

TUB-060target undisclosed

Discovery

Preclinical

Phase I

solid cancers

TUB-060

Detailed Content Here

Partnered programs

Program

Discovery

Preclinical

Phase I

BMSmultitarget collaboration

Discovery

Preclinical

Phase I

BMS

Detailed Content Here

TUB-010/TEQ102targeting CD30

Discovery

Preclinical

Phase I

T-cell & Hodgkin's Lymphoma

TUB-010/TEQ102

Detailed Content Here

Expanded Access Policy

Expanded access, also known as “Compassionate Use”, offers a potential pathway for patients with immediately life-threatening conditions or serious diseases to access investigational drugs for treatment when comparable or satisfactory alternative therapies are not available.

Tubulis products are investigational drugs that have not yet received marketing approval or clearance from the FDA, EMA, or any other regulatory agency. The effectiveness of investigational products in treating the condition is uncertain, and their use may lead to unexpected serious side effects. Currently, Tubulis does not have an expanded access program available for our investigational products beyond clinical trials. Our primary focus is on enrolling and conducting the necessary clinical trials to bring innovative, safe, and effective products to patients as swiftly as possible.

Participation in one of our clinical trials is presently the sole means to access Tubulis’ investigational products. We encourage patients and healthcare providers interested in our investigational products to explore details about our ongoing studies on clinicaltrials.gov and our website.

For further information, please contact us at contact@tubulis.com.